BioMarin Pharmaceutical (BMRN) Jumps: Stock Rises 6.6%

BMRN ANIP

BioMarin Pharmaceutical Inc. (BMRN - Free Report) was a big mover last session, as its shares rose almost 7% on the day. The upside was driven by positive interim results of an open-label Phase 1/2 study of BMN 270 – an investigational gene therapy treatment for severe hemophilia A. This also led to far more shares changing hands than in a normal session. Yesterday’s rally breaks the recent trend for the company, as the stock is now trading above the volatile price range of $77.80 to $93.76 in the past one-month time frame.

Over the last 30 days, the company witnessed one positive estimate revision and the Zacks Consensus Estimate also moved higher, suggesting more solid trading ahead. So make sure to keep an eye on this stock going forward to see if yesterday’s jump can turn into more strength down the road.

BioMarin Pharmaceutical currently has a Zacks Rank #3 (Hold) while its Earnings ESP is positive.

A better-ranked biomedical stock is ANI Pharmaceuticals, Inc. (ANIP - Free Report) with a Zacks Rank #1 (Strong Buy).

Is BMRN going up? Or down? Predict to see what others think: Up or Down

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>

Zacks Names "Single Best Pick to Double"

From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.

It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.

This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.

Free: See Our Top Stock and 4 Runners Up >>